12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Absorica regulatory update

FDA approved an NDA from Cipher for Absorica Cip-isotretinoin to treat severe recalcitrant nodular acne. The approval triggers a $9 million milestone payment to Cipher from Ranbaxy Laboratories...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >